Robert Deans, PhD BlueRock Therapeutics

Robert Deans, PhD

Robert Deans, PhD BlueRock Therapeutics

Dr Deans is Chief Technology Officer at BlueRock Therapeutics, a biotechnology company creating innovative cell therapeutics by harnessing gene editing tools and pluripotent stem cell biology.

Prior to BlueRock, he was CSO at Rubius Therapeutics, a red cell therapeutics platform company.

Dr Deans was previously EVP at Athersys, Inc, an adult stem cell therapeutics company now in late stage clinical development, and prior to that VP of Research at Osiris, Inc, developing the Prochymal MSC based product line.

Dr Deans was also experienced in hematopoietic stem cell isolation and gene therapy while Director at the Immunotherapy Division of Baxter Healthcare.

Dr. Deans has also contributed to numerous Regulatory and industry commercialization workshops and societies.